fda restrictions on bpc-157 compounding BREAKING NEWS! The FDA's Pharmacy Advisory Committee has voted in support of four highly anticipated peptides—a major step toward broader patient access through licensed compounding pharmacies. Swipe to see the peptides FDA advisers back BPC-157 and

Track your dose progression against these numbers to know exactly when you will need your next vial

Injection sites for extensor tendonitis should be placed subcutaneously on the dorsal (back) wrist surface, approximately 1-2 inches from the point of maximum tenderness

For peptides that target specific areas, like BPC-157 for tendon injuries , some protocols suggest injecting as close to the affected area as practical

This includes long-term trials that test both the effectiveness and safety, to determine side effects and whether certain groups of people may not be able to take it, such as due to other medications or health conditions

Some are recovering from a specific injury

The solution should be completely clear and colorless